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ABSTRACT
Background The prevalence of asymptomatic
tuberculosis (TB) in recently diagnosed HIV-1-infected
persons attending pre-antiretroviral therapy (ART) clinics
is not well described. In addition, it is unclear if the
detection of Mycobacterium tuberculosis in these
patients clearly represents an early asymptomatic phase
leading to progressive disease or transient excretion of
bacilli.
Objective To describe the prevalence and outcome of
subclinical TB disease in HIV-1-infected persons not
eligible for ART.
Methods The study was conducted in 274
asymptomatic ART-naı¨ve HIV-1-infected persons in
Khayelitsha Day Hospital, Cape Town, South Africa. All
participants were screened for TB using a symptom
screen and spoligotyping was performed to determine
genotypes.
Results The prevalence of subclinical TB disease was
8.5% (95% CI 5.1% to 13.0%) (n¼18; median days to
culture positivity 17 days), with 22% of patients being
smear-positive. Spoligotyping showed a diverse variety
of genotypes with all paired isolates being of the same
spoligotype, effectively excluding cross-contamination.
56% of patients followed up developed symptoms 3 days
to 2 months later. All were well and still in care
6e12 months after TB diagnosis; 60% were started on
ART. A positive tuberculin skin test (OR 4.96, p¼0.064),
low CD4 count (OR 0.996, p¼0.06) and number of years
since HIV diagnosis (OR 1.006, p¼0.056) showed trends
towards predicting TB disease.
Conclusion This study found a high prevalence but good
outcome (retained in care) of subclinical TB disease in HIV-
1-infected persons. The results suggest that, in high HIV/
TB endemic settings, a positive HIV-1 test should prompt
TB screening by sputum culture irrespective of symptoms,
particularly in those with a positive tuberculin skin test,
longer history of HIV infection and low CD4 count.
Operational difficulties in resource-constrained settings
with respect to screening with TB culture highlight the
need for rapid and affordable point-of-care tests to identify
persons with clinical and subclinical TB disease.
INTRODUCTION
Tuberculosis (TB) is the most common opportu-
nistic infection and is the leading cause of mortality
in HIV-1-infected persons.1 Reducing the morbidity
and mortality of TB in HIV-1 co-infected
persons requires an improved understanding of the
epidemiology of TB, including the prevalence of
and risk factors for latent TB infection and TB
disease in this population.
South Africa has a very high incidence of TB
with an estimated national incidence rate of 948/
100 000 population per year in 2007. Against this
background of high prevalence, short course
directly observed therapy, which is predominantly
dependent on passive case ﬁnding, has been
implemented with considerable success. However,
this passive approach has some recognised weak-
nesses. Notably, it assumes that persons with TB
will have symptoms as a trigger to seek investiga-
tion for TB. However, waiting for symptomatic
persons to present for TB screening can result in
a delay in investigation for TB and consequently
continued transmission in the community as well
as a potentially worse outcome.
TB infection is considered to lead to one of three
outcomes: 5% are thought to progress to active TB
disease (primary TB) while the majority develop an
acquired immune response but no signs or symp-
toms of disease (latent TB infection). Among those
with latent infection there is a 10% risk per lifetime
(up to 10% risk per year in HIV-1-infected persons)
of progressing to active TB (post-primary TB). It
has recently been proposed that the latent TB
infection phase, rather than being static, comprises
a more dynamic spectrum of responses to TB
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infection that includes innate immune, acquired immune,
quiescent infection, active infection or clinical disease.2 Of note,
this spectrum predicts the existence of a minimally symptom-
atic phase of infection during which patients nevertheless
become infectious.
METHODS
Study location and design
The study was conducted at site B Day Hospital, a primary care
hospital in the informal township of Khayelitsha. Located on
the outskirts of Cape Town, Khayelitsha has a population of
over 400 000 and a TB case notiﬁcation rate of over 1600/
100 000, 70% of which are associated with HIV-1. The study
was conducted as part of a larger cross-sectional TB diagnostics
study.
Participants
Study participants were recruited from the HIV pre-anti-
retroviral therapy (ART) clinic between February 2008 and
March 2010. Written informed consent was obtained from all
participants and the University of Cape Town research ethics
committee approved the study (REC 012/2007).
Two hundred and seventy-four asymptomatic ART-naïve
HIV-1-infected persons were recruited. At recruitment all
participants were screened for TB and a baseline CD4 count was
performed. All participants received the tuberculin skin test
(TST) using 2 TU tuberculin PPD RT23 injected intradermally
into the volar aspect of the forearm. All those with a skin
induration diameter of $5 mm had a chest x-ray performed and
were started on isoniazid preventive therapy for 6 months if the
x-ray was normal. For comparison, 162 HIV-1-infected patients
with TB symptoms diagnosed with culture-positive TB were
recruited from the TB clinic in the same setting.
TB screening
All participants were screened for TB using a symptom screen
(cough of any duration, fever, unintentional weight loss, loss of
appetite and drenching night sweats) and study-speciﬁc induced
sputum samples were collected. Microscopy and culture were
performed on the collected specimens and processed at
a national reference laboratory in Cape Town. A TB case was
deﬁned as one with at least one culture-positive sputum spec-
imen in the presence (symptomatic TB cases) or absence
(asymptomatic subclinical TB cases) of symptoms.
Spoligotyping
Genomic DNA was prepared as previously described.3 Twenty-
six heat-killed isolates were prepared from MGIT cultures and
two heat-killed isolates were prepared from LowensteineJensen
slope cultures. The DNA was used to perform spoligotyping as
previously described4 using a commercially available kit from
Ocimum Biosolutions BV, The Netherlands. The hybridisation
patterns obtained were used to assign the isolates to genotype
families using the SPOTCLUST SpolDB3 database.5
Statistical methods
Baseline characteristics were tabulated and compared between
groups using the c2 test for categorical variables and Wilcoxon
test for continuous variables that were not normally distributed.
Predictors of disease status were analysed by logistic regression.
The model was built both manually and using the stepwise
method including variables with a p value <0.10. Subsequent
inclusion of other variables in turn did not improve the ﬁt of the
model to the data (using the Pearson c2 goodness-of-ﬁt test) and
these variables were therefore excluded. Median CD4 counts
were compared across the symptomatic TB, asymptomatic TB
and asymptomatic non-TB groups using the KruskaleWallis
test. All p values were two-sided and p values <0.05 were
considered statistically signiﬁcant. All data were analysed using
Stata 10.0 (StataCorp) and GraphPad Prism V.5.0 software.
RESULTS
Prevalence of asymptomatic culture-positive TB
Of the 274 asymptomatic HIV-1-infected persons recruited,
sputum samples were obtained from 213 (ﬁgure 1). Overall, 18
(8.5%, 95% CI 5.1% to 13.0%) were diagnosed with TB disease.
A summary of the characteristics and outcomes of these patients
is shown in the online supplement. Seventeen were found to be
TB culture-positive on at least one specimen (median days to
culture positivity 17 days), with three having an abnormal x-ray.
Four of the 18 (22%) were sputum smear microscopy positive.
One patient was diagnosed with TB solely on the basis of an
x-ray reviewed by two doctors at the TB clinic while one person
was diagnosed with culture-positive TB isolated from a cold
abscess of the elbow. Four patients had negative TST results and
therefore did not have an x-ray performed. These patients had
moderate to severe immunosuppression with CD4 counts
ranging from 11 to 250. Of the 14 patients in whom an x-ray
was performed, 10 patients (71%) had normal x-rays. Face-to-
face interviews were conducted with 11 of the 18 patients and
folder reviews were undertaken of a further ﬁve patients 1 year
after TB diagnosis. Although all participants had no TB symp-
toms at baseline, 9 of the 16 (56%) developed symptoms 3 days
to 2 months later (median 28 days after diagnosis), including one
Figure 1 Recruitment flow diagram of participants into the study. HCT,
HIV counselling and testing.
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patient who was admitted to hospital with disseminated TB
10 days after recruitment (patient 1 in table 1 in the online
supplement). Seven of the 16 received isoniazid preventive
therapy for up to 3 months. There was no difference in the
proportion that developed symptoms between those who did
and did not receive isoniazid preventive therapy (57% vs 56%).
All 16 were started on and completed TB treatment irrespective
of whether symptoms subsequently developed and were still in
care 6e12 months after TB diagnosis and treatment; 60%
became eligible for and were started on ART in accordance with
South African national guidelines.
At baseline a greater proportion of the asymptomatic TB
group had a TST $5 mm than those with no TB (78% vs 56%;
p¼0.051) and a higher proportion of asymptomatic TB patients
had CD4 counts # 200 compared with the non-TB group
(p¼0.055). There was no statistically signiﬁcant difference
between the two groups at baseline with respect to all other
characteristics measured (table 1).
Having found a high prevalence of asymptomatic disease, we
wished to exclude cross-contamination as a possible cause of
culture-positive results using spoligotyping. We found a diverse
variety of genotypes (see table 1 in the online supplement),
with all paired isolates being of the same spoligotype, thereby
effectively excluding cross-contamination as a source of culture-
positive results.
Comparison with symptomatic TB cases
We examined the CD4 count distribution, proportion of smear-
negative culture-positive patients and days to culture positivity
in asymptomatic TB cases and compared them with symp-
tomatic TB cases and a control group of asymptomatic HIV-1-
infected persons with no TB. Patients in all three groups came
from the same setting, had similar baseline characteristics and
were recruited under the same conditions. CD4 counts were
highest in those with no TB (median 322, IQR 225e446) and
lowest in symptomatic TB patients (median 148, IQR 64e259),
with the median CD4 count of asymptomatic TB cases being
between them (median 249, IQR 170e332; table 2). This trend
to a decline in CD4 count was statistically signiﬁcant (p<0.001).
In addition, there was a signiﬁcant difference in the median days
to culture positivity in the symptomatic and asymptomatic TB
groups with a median of 17 days (IQR 12e39) in those with
a negative TB screen and 7 days (IQR 6e12) in symptomatic TB
cases (p<0.001, ﬁgure 2). Seventy per cent of asymptomatic TB
patients had smear-negative TB compared with only 16% of
symptomatic TB patients (p<0.001), suggesting that the
bacterial burden is lower in patients with subclinical TB.
Risk factors for asymptomatic TB disease
Of the asymptomatic HIV-1-infected persons recruited, 69%
were recruited from the HIV pre-ART clinic and 31% from the
HIV counselling and testing clinic (HCT) within 30 days of
HIV-1 diagnosis. There was no signiﬁcant difference in the
prevalence of TB disease between persons recruited from the
two clinics. In addition, there was no signiﬁcant difference in
CD4 counts (p¼0.600) between persons recruited from the HCT
clinic (median CD4 count 326 (IQR 166e456); median time
since HIV-1 diagnosis 6 days (IQR 0e13)) and those from the
HIV-1 clinic (median CD4 count 305 (IQR 230e433); median
time since HIV-1 diagnosis 776 days (IQR 278e1585)). These
two groups did not differ signiﬁcantly in other baseline charac-
teristics measured.
To further explore the risk factors for asymptomatic TB
disease, we conducted multivariable logistic regression on all
asymptomatic persons with the presence or absence of TB
disease as an outcome variable (table 3). A positive TST (OR
4.96, p¼0.064), a longer history of HIV infection (OR 1.006,
p¼0.056) and a low CD4 count (OR 0.996, p¼0.060) showed
trends (albeit not statistically signiﬁcant) towards being
predictive of subclinical TB disease.
DISCUSSION
We report an 8.5% prevalence of asymptomatic TB disease
among HIV-1-infected persons not receiving ART in Cape Town.
We also showed that most of these cases progressed clinically
with development of symptoms a median of 28 days after
diagnosis, as well as good adherence and treatment outcome at
follow-up 6e12 months after TB diagnosis. This suggests an
increasing bacterial load after initial screening and that screening
before the likely development of symptoms was beneﬁcial in
indicating the presence of actively replicating bacilli. This early
Table 1 Baseline characteristics by TB disease group
Non-TB
n (%)
Asymptomatic TB
n (%) p Value
Overall
N (%)
Sex
Female 200 (80) 15 (83) 0.732 215 (80)
Male 50 (20) 3 (17) 53 (20)
Previous TB
No 193 (85) 13 (75) 0.286 205 (84)
Yes 34 (15) 4 (25) 38 (16)
BCG scar
No 109 (54) 10 (59) 0.699 119 (54)
Yes 93 (46) 7 (41) 100 (46)
TB contact
No 176 (80) 13 (76) 0.756 189 (79)
Yes 45 (20) 4 (24) 49 (21)
CD4 count
<200 45 (20) 7 (39) 0.055 52 (21)
$200 183 (80) 11 (61) 194 (79)
Tuberculin skin test
<5 mm 98 (44) 4 (22) 0.051 102 (42)
$5 mm 124 (56) 14 (78) 138 (58)
Smoker
No 164 (81) 12 (75) 0.546 176 (81)
Yes 38 (19) 4 (25) 42 (19)
Alcohol consumption
No 159 (79) 11 (65) 0.183 170 (78)
Yes 43 (21) 6 (35) 49 (22)
Time in Khayelitsha
<6 months 5 (3) 0 (0) 0.212 5 (2)
6e12 months 6 (3) 2 (12.5) 8 (4)
1e5 years 43 (22) 2 (12.5) 45 (21)
>5 years 140 (72) 12 (75) 152 (73)
Medians (IQR)
Age 30 (27e37) 34 (27e38) 0.365 31
CD4 cell count /mm3 322 (225e446) 249 (170e332) 0.026 312
Body mass index 26 (22e31) 24 (23e27) 0.140 26
Days since HIV-1
diagnosis
319 (17e1118) 640 (20e1389) 0.313 325
Table 2 CD4 count gradient across TB disease groups
CD4 count IQR
p Value
(KruskaleWallis)
Asymptomatic, no TB disease 322 225e446 <0.0001
Asymptomatic, TB disease 249 170e332
Symptomatic, TB disease 148 64e259
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diagnosis resulted in patients receiving treatment for TB earlier
than would otherwise have occurred. This ﬁnding has potential
signiﬁcance for TB control programmes implemented in this
setting, in addition to wider public health implications.
Our ﬁndings support the hypothesis that TB infection pres-
ents as a spectrum from innate immune clearance to clinical
disease and development of symptoms.2 In a previous study we
demonstrated a signiﬁcant correlation between bacterial load
(measured by degree of smear positivity in TB patients) and the
interferon gamma release assay (IGRA) response, as well as
a trend towards a correlation between the IGRA response and
days to culture positivity.6 This suggested an association
between bacterial load and days to culture positivity. Using days
to culture positivity as a marker of bacterial load, our result
showing a longer period to culture positivity in asymptomatic
than in symptomatic persons suggests a higher bacterial load in
symptomatic persons than in asymptomatic persons. Our
ﬁnding of a greater proportion of smear-negative TB cases in the
asymptomatic cases than in the symptomatic TB cases (70% vs
16%) also supports this interpretation. In addition, by
comparing asymptomatic persons with no TB, asymptomatic
cases with TB and symptomatic TB cases, we demonstrate
a spectrum in CD4 count distribution with decreasing CD4
counts across these three groups.
Several studies have reported subclinical asymptomatic TB
disease as deﬁned by culture-positive TB in the absence of TB
symptoms. Swaminathan et al screened HIV-1-infected persons
in India and reported a 4% prevalence of unrecognised TB in
HIV-1-infected persons with minimal or no symptoms, normal
chest x-rays, negative smears and different levels of immuno-
suppression.7 Mtei et al recruited HIV-1-infected persons with
CD4 counts >200/mm3 and found a 15% prevalence of TB, 29%
of which was subclinical.8 Patients with subclinical TB had
a better prognosis than those with clinical disease, with no
clinical predictors of subclinical TB identiﬁed. In addition, an
intensiﬁed TB case-ﬁnding study by Shah et al on newly diag-
nosed HIV-1-infected persons in Ethiopia found that 16% of all
prevalent TB cases were asymptomatic.9 These studies highlight
the entity that is subclinical TB. A TB prevalence survey in
Zimbabwe found that 41% of all prevalent cases were subclinical
at the time of screening, 82% of whom had developed symptoms
within a few weeks of follow-up; no signiﬁcant risk factors for
prevalent culture-positive disease were found.10 One theory
suggested is that, in a healthcare system with a strong TB
diagnosis and treatment programme, severe cases are identiﬁed
early leaving TB patients with fewer clinical symptoms to be
identiﬁed through provider-initiated TB screening.11 Results
from a meta-analysis of yield of HIV-1-associated TB during
intensiﬁed case-ﬁnding suggested that TB cases diagnosed by
active screening might be less likely to adhere to treatment,
resulting in poor outcomes.12 In our study, all patients started on
TB treatment completed the 6-month course with good
outcomes and remained in care at 6e12 months after treatment.
We also explored potential risk factors for TB disease in
asymptomatic HIV-1-infected persons. We found a trend
towards a TST $5 mm, lower CD4 count and increasing
number of days since HIV-1 diagnosis being associated with an
increased risk of TB disease. There was a 5% decrease in TB
disease risk for every increase in the CD4 count of 10 cells/mm3,
and an increase of 24% in the risk of TB disease for every year
after HIV-1 diagnosis. This raises concern about the possibility
of the association we report being linked to nosocomial trans-
mission of TB. However, when we compared the prevalence of
asymptomatic TB in those who had been in HIV care for
<30 days with those who had received a diagnosis of HIV-1
Figure 2 Scatterplot showing a comparison of number of days to
culture positivity in symptomatic and asymptomatic TB cases. ASx,
asymptomatic subclinical TB cases; Sx, symptomatic TB cases.
Table 3 Risk factors for asymptomatic TB disease
Univariate analysis Multivariable analysis
OR p Value OR (95% CI) p Value
CD4 cell count/mm3 0.996 0.035 0.996 (0.992 to 1.000) 0.060
Tuberculin skin test $5 mm 2.77 0.081 4.96 (0.990 to 17.662) 0.064
Days since HIV-1 diagnosis 1.00 0.095 1.006 (0.999 to 1.010) 0.056
Age (years) 1.02 0.496
Male sex 0.80 0.732
Body mass index 0.92 0.112
History of previous TB 1.89 0.293
Smoker 1.44 0.548
BCG scar presence 0.82 0.699
Contact with TB 1.20 0.756
Alcohol consumption 2.02 0.190
Time in Khayelitsha >5 years 1.16 0.808
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$30 days earlier and were established in the pre-ART clinic,
there was no statistically signiﬁcant difference in the prevalence
of subclinical TB.
The question of the public health relevance of asymptomatic
persons found to be TB culture-positive with respect to the
contribution to transmission is potentially important. It has
been shown that smear-negative culture-positive TB is trans-
missible but less infectious than smear-positive disease, with
smear-negative disease being responsible for up to 17% of
transmitted TB.13 In our study, 22% of asymptomatic cases were
smear positive and therefore more infectious; 56% progressed to
develop symptoms within 2 months, suggesting that they
would ultimately have been likely to contribute to transmission.
Limitations of the study
The speciﬁcity of culture can be affected by contamination as
a result of laboratory manipulations. We excluded cross-
contamination as a cause of culture-positive results by strain
typing of isolates. In addition, the reference laboratory where
the samples were processed has previously reported low
contamination rates; of 500 dummy sputum samples, none were
false positive for Mycobacterium tuberculosis.
CONCLUSION
Our results show a high prevalence of asymptomatic TB disease
in HIV-1 co-infected persons in Cape Town. These results
suggest that, in high HIV/TB prevalence settings, a diagnosis of
HIV-1 should prompt a TB test by sputum culture even in the
absence of symptoms, particularly in persons with positive TST
reactions, lower CD4 counts and a longer history of HIV. The
WHO guidelines for isoniazid preventive therapy in resource-
constrained settings recommend that all HIV-infected persons,
irrespective of the degree of immunosuppression, should be
screened for TB and isoniazid preventive therapy provided if no
symptoms.14 A recent meta-analysis by Getahun et al that aimed
to develop a standardised TB screening tool for HIV-infected
persons found that the clinical rule of any of the following
symptoms (current cough, night sweats, fever or weight loss)
excluded active TB disease with a sensitivity of 78.9% and
speciﬁcity of 49.6%.15 However, it was noted that the negative
predictive value of this screening tool was dependent on the
prevalence of TB in the screened population, ranging from 97.7%
at a TB prevalence of 5% to 90% at a TB prevalence of 20%.
Isoniazid preventive therapy has been shown to signiﬁcantly
decrease the incidence of TB in HIV-infected persons, but is not
widely implemented owing to reservations about effective
exclusion of active TB. Therefore, in most high-burden low-
resource settings, Getahun et al show that this clinical tool will
be sufﬁcient to exclude active TB, permitting implementation of
isoniazid preventive therapy. However, in settings like the
Western Cape of South Africa with one of the most intense TB
transmission rates in the world, our results show that this
clinical tool will miss 8.5% of HIV-infected persons with
subclinical TB.
However, we acknowledge the operational difﬁculties in the
majority of resource-constrained settings with respect to
screening with TB culture, highlighting the need for new rapid
and affordable point-of-care diagnostic tests to identify persons
with clinical and subclinical TB disease.
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